ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Trastuzumab is on this study

  • No treatment in the record names it; a reading of the whole record found it given.
  • Claude Opus 5.5 judged it given beside what the study tests (care). Nov 2, 2026, 3:40 AM UTC“Standard for HER2-positive patients; ctDNA guides adjuvant therapy”
  • The role rule had no answer: no treatment entry names it.
  • So Trastuzumab's page lists this study under “Given beside what is tested”.
1 links1 made here, not in the record1 judgments1 judge (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Record updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT07508956Feasibility of CirculatingTumor DNA Based MinimalResidual Disease-GuidedAdjuvant Therapy in LocallyAdvanced Gastric CancerWith Neoadjuvant TreatmentShanghai Zhongshan HospitalPhase 3 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 20 · ClinicalTrials.gov record · Version of 2026-11-20Version of 2026-11-20DRUGSTrastuzumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · Background · careBackground · care

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 20 · changes seen, not judgments
Nov 2Trastuzumabmade hereClaude Opus 5.5Background · careCurrent